Literature DB >> 25316212

Bendamustine is effective in T-cell prolymphocytic leukaemia.

Charles Herbaux1, Philippe Genet, Krimo Bouabdallah, Jean-Michel Pignon, Houria Debarri, Stéphanie Guidez, Sarah Betrian, Xavier Leleu, Thierry Facon, Franck Morschhauser, Gandhi Damaj, Bruno Cazin, Loïc Ysebaert.   

Abstract

Entities:  

Keywords:  T-PLL; alemtuzumab; bendamustine; salvage therapy

Mesh：

Substances：

Year:  2014        PMID： 25316212     DOI： 10.1111/bjh.13175

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  15 in total

Review 1.  Mature T-cell leukemias: Molecular and Clinical Aspects.

Authors:  Nathanael G Bailey; Kojo S J Elenitoba-Johnson
Journal:  Curr Hematol Malig Rep       Date:  2015-12       Impact factor: 3.952

Review 2.  Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia.

Authors:  Philipp B Staber; Marco Herling; Mar Bellido; Eric D Jacobsen; Matthew S Davids; Tapan Mahendra Kadia; Andrei Shustov; Olivier Tournilhac; Emmanuel Bachy; Francesco Zaja; Kimmo Porkka; Gregor Hoermann; Ingrid Simonitsch-Klupp; Claudia Haferlach; Stefan Kubicek; Marius E Mayerhoefer; Georg Hopfinger; Ulrich Jaeger; Claire Dearden
Journal:  Blood       Date:  2019-07-10       Impact factor: 22.113

3.  T-cell prolymphocytic leukemia in an adolescent with ataxia-telangiectasia: novel approach with a JAK3 inhibitor (tofacitinib).

Authors:  Geling Li; Emily Waite; Julie Wolfson
Journal:  Blood Adv       Date:  2017-12-18

Review 4.  Prolymphocytic Leukemia: New Insights in Diagnosis and in Treatment.

Authors:  Aude Collignon; Anne Wanquet; Elsa Maitre; Edouard Cornet; Xavier Troussard; Thérèse Aurran-Schleinitz
Journal:  Curr Oncol Rep       Date:  2017-04       Impact factor: 5.075

Review 5.  Carmustine replacement in intensive chemotherapy preceding reinjection of autologous HSCs in Hodgkin and non-Hodgkin lymphoma: a review.

Authors:  G Damaj; J Cornillon; K Bouabdallah; R Gressin; S Vigouroux; T Gastinne; F Ranchon; H Ghésquières; G Salles; I Yakoub-Agha; E Gyan
Journal:  Bone Marrow Transplant       Date:  2017-01-23       Impact factor: 5.483

6.  First reported case of BRAF V600E mutation in T-cell prolymphocytic leukaemia.

Authors:  Stephen Dong; Tarek Khedro; Pamela Ward; Louis Dubeau; Bassam Yaghmour; Imran Siddiqi; George Yaghmour
Journal:  Br J Haematol       Date:  2020-07-25       Impact factor: 6.998

Review 7.  Advances in the understanding and management of T-cell prolymphocytic leukemia.

Authors:  Kamel Laribi; Pierre Lemaire; Jeremy Sandrini; Alix Baugier de Materre
Journal:  Oncotarget       Date:  2017-11-01

8.  Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL.

Authors:  A Schrader; G Crispatzu; S Oberbeck; P Mayer; S Pützer; J von Jan; E Vasyutina; K Warner; N Weit; N Pflug; T Braun; E I Andersson; B Yadav; A Riabinska; B Maurer; M S Ventura Ferreira; F Beier; J Altmüller; M Lanasa; C D Herling; T Haferlach; S Stilgenbauer; G Hopfinger; M Peifer; T H Brümmendorf; P Nürnberg; K S J Elenitoba-Johnson; S Zha; M Hallek; R Moriggl; H C Reinhardt; M-H Stern; S Mustjoki; S Newrzela; P Frommolt; M Herling
Journal:  Nat Commun       Date:  2018-02-15       Impact factor: 14.919

9.  Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia (T-PLL).

Authors:  P Jain; E Aoki; M Keating; W G Wierda; S O'Brien; G N Gonzalez; A Ferrajoli; N Jain; P A Thompson; E Jabbour; R Kanagal-Shamanna; S Pierce; A Alousi; C Hosing; I Khouri; Z Estrov; J Cortes; H Kantarjian; F Ravandi; T M Kadia
Journal:  Ann Oncol       Date:  2017-07-01       Impact factor: 32.976

Review 10.  Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel - an update.

Authors:  Bruce D Cheson; Wolfram Brugger; Gandhi Damaj; Martin Dreyling; Brad Kahl; Eva Kimby; Michinori Ogura; Eckhart Weidmann; Clemens-Martin Wendtner; Pier Luigi Zinzani
Journal:  Leuk Lymphoma       Date:  2015-11-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.